Suppr超能文献

L型氨基酸转运体LAT1和LAT2的药代动力学作用。

Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2.

作者信息

del Amo Eva M, Urtti Arto, Yliperttula Marjo

机构信息

Centre for Drug Research, University of Helsinki, Helsinki, Finland.

出版信息

Eur J Pharm Sci. 2008 Oct 2;35(3):161-74. doi: 10.1016/j.ejps.2008.06.015. Epub 2008 Jul 5.

Abstract

LAT1 and LAT2 are heterodimeric large amino acid transporters that are expressed in various tissues, including the intestinal wall, blood-brain barrier, and kidney. These transporters consist of membrane spanning light chain and heavy chain, and they act as 1:1 exchangers in concert with other amino acid transporters. Only a few drugs (less than 10) are substrates of LAT1 and LAT2, including L-DOPA, alpha-methyldopa, melphalan, and gabapentin. The mechanisms and substrates have been mostly elucidated using mammalian cells and Xenopus oocytes. The in vivo relevance of LAT1 and LAT2 in pharmacokinetics is obscure, because contradictory findings have been reported. It is difficult to make quantitative pharmacokinetic conclusions about LAT1 and LAT2. This is due to the possible involvement of other transporters (including cross-linked heterodimers of light chain with different heavy chains, other overlapping transporters, for example TAT1), competing endogenous amino acids, and saturation phenomena. This review presents the current functional knowledge on LAT1 and LAT2 with emphasis on their potential involvement in pharmacokinetics.

摘要

LAT1和LAT2是异二聚体大氨基酸转运体,在包括肠壁、血脑屏障和肾脏在内的多种组织中表达。这些转运体由跨膜轻链和重链组成,它们与其他氨基酸转运体协同作用,作为1:1的交换体。只有少数几种药物(不到10种)是LAT1和LAT2的底物,包括左旋多巴、α-甲基多巴、美法仑和加巴喷丁。其机制和底物大多是通过哺乳动物细胞和非洲爪蟾卵母细胞来阐明的。LAT1和LAT2在药代动力学中的体内相关性尚不明确,因为已有相互矛盾的研究结果报道。很难对LAT1和LAT2做出定量的药代动力学结论。这是由于可能涉及其他转运体(包括轻链与不同重链的交联异二聚体、其他重叠的转运体,例如TAT1)、竞争性内源性氨基酸以及饱和现象。本综述介绍了目前关于LAT1和LAT2的功能知识,重点强调了它们在药代动力学中的潜在作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验